Reported results
- Total revenues were $50,647 million for the third quarter of 2026.
- Premium and service revenues were $45,105 million for the third quarter of 2026.
- The GAAP Health benefits ratio was 92.7% for the third quarter of 2026.
- The GAAP SG&A expense ratio was 7.2% for the third quarter of 2026.
- The non-GAAP adjusted SG&A expense ratio was 6.5% for the third quarter of 2026.
- Total cash flow used in operations was $3,669 million for the third quarter of 2026.
Guidance
- Full year 2026 GAAP diluted EPS guidance is greater than $3.46.
- Full year 2026 adjusted diluted EPS guidance is greater than $5.20.
- Full year 2026 HBR guidance range is 90.4% to 91.1%.
- Full year 2026 interest expense guidance range is $600 million to $620 million.
Price and volatility reaction
The stock moved +1.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -9.2 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 68.03 | 2026-10-26 |
| Close after release | 68.71 | 2026-10-27 |
| Realised move | +1.0% | close to close |
| 30d ATM IV change | -9.2 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-26 (8-K, Item 2.02). Read the original filing on sec.gov.
